Hemolytic disease of the newborn

For patient information on Hemolytic disease of the newborn, click here

For patient information on Rh incompatibility, click here

For patient information on ABO incompatibility, click here

HDN
ICD-10	P55
ICD-9	773
DiseasesDB	5545
MedlinePlus	001298

WikiDoc Resources for Hemolytic disease of the newborn
Articles
Most recent articles on Hemolytic disease of the newborn Most cited articles on Hemolytic disease of the newborn Review articles on Hemolytic disease of the newborn Articles on Hemolytic disease of the newborn in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hemolytic disease of the newborn Images of Hemolytic disease of the newborn Photos of Hemolytic disease of the newborn Podcasts & MP3s on Hemolytic disease of the newborn Videos on Hemolytic disease of the newborn
Evidence Based Medicine
Cochrane Collaboration on Hemolytic disease of the newborn Bandolier on Hemolytic disease of the newborn TRIP on Hemolytic disease of the newborn
Clinical Trials
Ongoing Trials on Hemolytic disease of the newborn at Clinical Trials.gov Trial results on Hemolytic disease of the newborn Clinical Trials on Hemolytic disease of the newborn at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hemolytic disease of the newborn NICE Guidance on Hemolytic disease of the newborn NHS PRODIGY Guidance FDA on Hemolytic disease of the newborn CDC on Hemolytic disease of the newborn
Books
Books on Hemolytic disease of the newborn
News
Hemolytic disease of the newborn in the news Be alerted to news on Hemolytic disease of the newborn News trends on Hemolytic disease of the newborn
Commentary
Blogs on Hemolytic disease of the newborn
Definitions
Definitions of Hemolytic disease of the newborn
Patient Resources / Community
Patient resources on Hemolytic disease of the newborn Discussion groups on Hemolytic disease of the newborn Patient Handouts on Hemolytic disease of the newborn Directions to Hospitals Treating Hemolytic disease of the newborn Risk calculators and risk factors for Hemolytic disease of the newborn
Healthcare Provider Resources
Symptoms of Hemolytic disease of the newborn Causes & Risk Factors for Hemolytic disease of the newborn Diagnostic studies for Hemolytic disease of the newborn Treatment of Hemolytic disease of the newborn
Continuing Medical Education (CME)
CME Programs on Hemolytic disease of the newborn
International
Hemolytic disease of the newborn en Espanol Hemolytic disease of the newborn en Francais
Business
Hemolytic disease of the newborn in the Marketplace Patents on Hemolytic disease of the newborn
Experimental / Informatics
List of terms related to Hemolytic disease of the newborn

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Haemolytic disease of the newborn, also known as HDN or Erythroblastosis fetalis, is an alloimmune condition that develops in a fetus, when the IgG antibodies that have been produced by the mother and have passed through the placenta include ones which attack the red blood cells in the fetal circulation. The red cells are broken down and the fetus can develop reticulocytosis and anaemia. This fetal disease ranges from mild to very severe, and fetal death from heart failure (hydrops fetalis) can occur. When the disease is moderate or severe, many erythroblasts are present in the foetal blood and so these forms of the disease can be called erythroblastosis fetalis (or erythroblastosis foetalis).

Symptoms

Hemolysis leads to elevated bilirubin levels. After delivery bilirubin is no longer cleared (via the placenta) from the neonate's blood and the symptoms of jaundice (yellowish skin and yellow discolouration of the whites of the eyes) increase within 24 hours after birth. Like any other severe neonatal jaundice, there is the possibility of acute or chronic kernicterus.

Profound anemia can cause high-output heart failure, with pallor, enlarged liver and/or spleen, generalized swelling, and respiratory distress. The prenatal manifestations are known as hydrops fetalis; in severe forms this can include petechiae and purpura. The infant may be stillborn or die shortly after birth.

Causes

Antibodies are produced when the body is exposed to an antigen foreign to the make-up of the body. If a mother is exposed to an alien antigen and produces IgG (as opposed to IgM which does not cross the placenta), the IgG will target the antigen, if present in the fetus, and may affect it in utero and persist after delivery. The three most common models in which a woman becomes sensitized toward (i.e., produces IgG antibodies against) a particular blood type are:

• Fetal-maternal hemorrhage can occur due to trauma, abortion, childbirth, ruptures in the placenta during pregnancy, or medical procedures carried out during pregnancy that breach the uterine wall. In subsequent pregnancies, if there is a similar incompatibility in the fetus, these antibodies are then able to cross the placenta into the fetal bloodstream to attach to the red blood cells and cause hemolysis. In other words, if a mother has anti-RhD (D being the major Rhesus antigen) IgG antibodies as a result of previously carrying a RhD-positive fetus, this antibody will only affect a fetus with RhD-positive blood.

• The woman may receive a therapeutic blood transfusion with an incompatible blood type. ABO blood group system and Rhesus blood group system typing are routine prior to transfusion. Suggestions have been made that women of child bearing age or young girls should not be given a transfusion with Rhc-positive blood or Kell₁-positive blood to avoid possible sensitization, but this would strain the resources of blood transfusion services, and it is currently considered uneconomical to screen for these blood groups.

• The third sensitization model can occur in women of blood type O. The immune response to A and B antigens, that are widespread in the environment, usually leads to the production of IgM anti-A and IgM anti-B antibodies early in life. On rare occasions, IgG antibodies are produced. In contrast, Rhesus antibodies are generally not produced from exposure to environmental antigens.

Serological diagnoses

• ABO system
  • ABO hemolytic disease of the newborn can range from mild to severe, but generally it is a mild disease.
    • anti-A antibodies
    • anti-B antibodies

• Rhesus system (the Rh d antigen and Rh d antibodies do not exist)
  • rhesus D hemolytic disease of the newborn (often called Rh disease) is the most common form of severe HDN. The disease varies from mild to severe.
  • rhesus E hemolytic disease of the newborn is a mild condition
  • rhesus c hemolytic disease of the newborn can range from a mild to severe disease - is the third most common form of severe HDN
  • rhesus e hemolytic disease of the newborn - rare
  • rhesus C hemolytic disease of the newborn - rare
  • antibody combinations (ie anti-Rhc and anti-RhE antibodies occurring together) - can be severe

• Kell system
  • anti-Kell hemolytic disease of the newborn
    • anti-K ₁ antibodies - disease ranges from mild to severe - over half of the cases are caused by multiple blood transfusions - is the second most common form of severe HDN
    • anti-K ₂ ,anti-K ₃ and anti-K ₄ antibodies - rare

• Other blood group antibodies (Kidd, Lewis, Duffy, MN, P and others).

Diagnosis

Not to be confused with Haemorrhagic disease of the newborn.

The diagnosis of HDN is based on history and laboratory findings:

Blood tests done on the newborn baby

• Biochemistry tests for jaundice
• Peripheral blood morphology shows increased reticulocytes. Erythroblasts (also known as nucleated red blood cells) occur in moderate and severe disease.

• Positive direct Coombs test (might be negative after fetal interuterine blood transfusion)

Blood tests done on the mother

• Positive indirect Coombs test

Treatment

Before birth, options for treatment include intrauterine transfusion or early induction of labor when pulmonary maturity has been attained, fetal distress is present, or 35 to 37 weeks of gestation have passed. The mother may also undergo plasma exchange to reduce the circulating levels of antibody by as much as 75%.

After birth, treatment depends on the severity of the condition, but could include temperature stabilization and monitoring, phototherapy, transfusion with compatible packed red blood, exchange transfusion with a blood type compatible with both the infant and the mother, sodium bicarbonate for correction of acidosis and/or assisted ventilation.

Rhesus-negative mothers who have had a pregnancy with/are pregnant with a rhesus-positive infant are given Rh immune globulin (RhIG) at 28 weeks during pregnancy and within 72 hours after delivery to prevent sensitization to the D antigen. It works by binding any fetal red cells with the D antigen before the mother is able to produce an immune response and form anti-D IgG. A drawback to pre-partum administration of RhIG is that it causes a positive antibody screen when the mother is tested which is indistinguishable from immune reasons for antibody production.

Complications

Complications of HDN could include kernicterus, hepatosplenomegaly, inspissated (thickened or dried) bile syndrome and/or greenish staining of the teeth, hemolytic anemia and damage to the liver due to excess bilirubin.

Similar conditions

Similar conditions include acquired hemolytic anemia, congenital toxoplasma and syphilis infection, congenital obstruction of the bile duct and cytomegalovirus infection.

References

• Geifman-Holtzman, O (1997). "Female allo-immunization with antibodies known to cause hemolytic disease". Obstetrics and Gynecology. 89 (2): 272–275. ISSN 0029-7844.
• Mollison, PL (1997). Blood Transfusion in Clinical Medicine (10th edition ed.). Oxford, UK: Blackwell Science. ISBN 0-86542-881-6. CS1 maint: Extra text (link)

See also

• Coombs test
• Hemolytic anemia
• Hematology
• Exchange transfusion

Template:WikiDoc Sources